Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TARSUS PHARMACEUTICALS, INC.

(TARS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
25.07(c) 25.25(c) 27.2(c) 27.7(c) 25(c) Last
9 972 16 168 61 161 8 248 41 633 Volume
-0.32% +0.72% +7.72% +1.84% -9.75% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 62,4 M - -
Net income 2021 -11,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -48,4x
Yield 2021 -
Sales 2022 6,55 M - -
Net income 2022 -122 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,27x
Yield 2022 -
Capitalization 517 M 517 M -
Capi. / Sales 2021 8,29x
Capi. / Sales 2022 78,9x
Nbr of Employees 20
Free-Float 71,3%
More Financials
Company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner,... 
More about the company
Ratings of Tarsus Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about TARSUS PHARMACEUTICALS, INC.
11/23Tarsus to Participate at Upcoming Virtual Investor Conferences
AQ
11/23Tarsus Pharmaceuticals Shares Gain After Oppenheimer Starts Coverage at Outperform
MT
11/23Oppenheimer Initiates Coverage on Tarsus Pharmaceuticals With Outperform Rating, $55 Pr..
MT
11/19TARSUS PHARMACEUTICALS : Corporate Presentation
PU
11/10Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021
AQ
11/10TARSUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/09Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Bu..
PU
11/09Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $1.24M
MT
11/09Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Bu..
GL
11/09Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/09Tarsus Pharmaceuticals, Inc. Expects Significant Advancements in the Pipeline
CI
11/04Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalenc..
AQ
11/04Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalenc..
CI
11/02Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference
GL
11/02Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference
GL
More news
News in other languages on TARSUS PHARMACEUTICALS, INC.
11/23Les actions de Tarsus Pharmaceuticals progressent après qu'Oppenheimer ait décidé de le..
11/09Earnings Flash (TARS) TARSUS PHARMACEUTICALS affiche un chiffre d'affaires de 1,24 mill..
11/02Tarsus Pharmaceuticals dépose une demande d'émission de titres mixtes pour un montant m..
More news
Analyst Recommendations on TARSUS PHARMACEUTICALS, INC.
More recommendations
Chart TARSUS PHARMACEUTICALS, INC.
Duration : Period :
Tarsus Pharmaceuticals, Inc. Technical Analysis Chart | TARS | US87650L1035 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 25,00 $
Average target price 57,17 $
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Bobak Azamian President, Chief Executive Officer & Director
Leonard M. Greenstein Chief Financial Officer
D. Michael Ackermann Chairman
Michael Holdbrook Vice President-Clinical Affairs
Sesha Neervannan Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
TARSUS PHARMACEUTICALS, INC.-39.51%517
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431